N/A N=61 A Study To Evaluate Methods To Evaluate Back Pain
Pain
Primary: Time to First Perceptible Relief (Confirmed by Meaningful Relief) — 96.5; 38.7; 54.0; 240 minutes — p=0.046
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=55 MiDAS II (Mild® Decompression Alternative to Open Surgery): Vertos Mild Patient Evaluation Study
Lumbar Spinal Stenosis
Primary: Changes in Back Pain as Measured by a 10-point Visual Analog Scale (VAS). — 3.59 units on a scale — p=<0.0001
N/A N=20 Clinical Investigation for New Filter to Ostomy Bags
Colostomy
Primary: Frequency of Ballooning in the Morfeus and SenSura Test Period. — 23; 11 percentage of bags
Phase 2 N=16 Amlodipine Plus Botulinum Toxin for Focal Dystonia
Focal Dystonia
Primary: Toronto Western Spasmodic Torticollis Rating Scale (TWSTR) Sum Score — -6.00; -3.23 units on a scale
Phase 2 N=41 NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer
Breast Cancer
Primary: Rate of Pathologic Complete Response in the Affected Breast After Protocol Therapy — 39 percentage of tumors
Phase 3 N=30 Mindfulness Versus Pharmacotherapy for Chronic Insomnia: A Pilot Study
Chronic Insomnia · Primary Insomnia
Primary: Pittsburgh Sleep Quality Index (PSQI) — 7.7; 9.2; 7.0; 8.2 units on a scale
Phase 2 N=223 A Study To Assess the Immune Response Following Administration Of Influenza and Pneumococcal Vaccines To Subjects With Rheumatoid Arthritis Receiving CP-690,550 Or Placebo
Rheumatoid Arthritis
Primary: Percentage of Participants With Satisfactory Humoral Response to the Pneumococcal Vaccine at Visit 3 (Day 64) — 45.1; 68.4; 31.6; 61.8 percentage of participants
N/A N=80 Neuroimaging Attentional Impairment During Abstinence
Smoking
Primary: Percent Signal Change in fMRI BOLD Signal Between RVIP Task and Control Task in Inferior Frontal Gyri (IFG) During Sustained Attention Task on Satiated Day — -0.0023…
Phase 1 N=230 Pharmacokinetics and Safety of Posaconazole Tablet in Participants at High Risk for Invasive Fungal Infections (MK-5592-065/P05615)
Fungal Infections
Primary: Average Concentration (Cavg) of Posaconazole Tablet — 981; 1580 ng/mL
Phase 3 N=431 Indomethacin Germinal Matrix Hemorrhage/Intraventricular Hemorrhage (GMH/IVH) Prevention Trial
Intraventricular Hemorrhage (IVH) · Bleeding in the Brain · Prematurity
Primary: IVH at 5 Postnatal Days — 25; 40 IVH
N/A N=11 Intracardiac T-wave Alternans and Ischemia
Ischemia
Primary: Number of Subjects With Positive T Wave Studies During a Coronary Intervention — 0 participants
Phase 3 N=640 Study Comparing Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept
Rheumatoid Arthritis
Primary: Participant Satisfaction on Day 84 for 2 Different Delivery Mechanisms for Etanercept, Modified Intent-to-treat Population — 8.3; 7.2 units on a scale — p=<0.001
Phase 2 N=152 Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45)
Alzheimer's Disease · Mild Cognitive Impairment
Primary: Change in ADAS-Cog for MCI Subjects — 5.664; -0.710 Scores on a scale
N/A N=9 T-wave Alternans and Intrathoracic Impedance Measurements
Congestive Heart Failure · Arrhythmias
Primary: Number of Positive Twave Studies and Concurrent Positive Optivol Measurement — 1; 1; 2; 5 participants
Phase 2 N=63 A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001)
Healthy
Primary: Adverse Events — 46; 28; 29; 36 number of reported events